Results 61 to 70 of about 5,671 (151)
More than a million men worldwide are diagnosed with prostate cancer every year. After androgen deprivation therapy (ADT), chemotherapy has been the only subsequent intervention to improve survival in the metastatic setting but has limitations for ...
Karin Purshouse, Andrew S. Protheroe
doaj +1 more source
Background Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular ...
Gustavo Werutsky +15 more
doaj +1 more source
Background: Abiraterone acetate was approved by FDA and EMA in April and September 2011, respectively for treatment of patients with casteration resistant prostate cancer and those previously treated with docetaxel.
Aloysius James +3 more
doaj
Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G.
Castellan P +6 more
doaj
BackgroundThere is limited evidence regarding the correlation between prostate-specific antigen (PSA) kinetics and clinical outcomes. Therefore, after regulating other covariates, we studied patients with castration-resistant prostate cancer who received
Hong Du +6 more
doaj +1 more source
Objective: This study aimed to evaluate the prognostic impact of intraductal carcinoma of the prostate (IDC-P) in patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate.
Hatice Bölek +3 more
doaj +1 more source
Introduction Abiraterone acetate has been shown to enhance overall survival and radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Sharath Kumar +7 more
doaj +1 more source
Xiang Wu,1,2 Qing-Jiang Xu,1,2 Ping-Zhou Chen,1,2 Chen-Bo Yu,1,2 Lie-Fu Ye,1,2 Tao Li1,2 1Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial ...
Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T
doaj
Joelle El-Amm,1 Rami Nassabein,1 Jeanny B Aragon-Ching2 1Division of Hematology and Oncology, Department of Internal Medicine, Lebanese American University, Beirut, Lebanon; 2GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA Abstract ...
El-Amm J, Nassabein R, Aragon-Ching JB
doaj
Yasser Rehman1, Jonathan E Rosenberg21Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA, USA; 2Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Prostate cancer is
Rosenberg JE, Rehman Y
doaj

